Pieris Pharmaceuticals Inc (PIRS) Expected to Post Quarterly Sales of $6.92 Million

Wall Street brokerages forecast that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will announce $6.92 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Pieris Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $4.50 million and the highest estimate coming in at $8.80 million. Pieris Pharmaceuticals posted sales of $18.15 million during the same quarter last year, which suggests a negative year-over-year growth rate of 61.9%. The business is scheduled to announce its next earnings report on Friday, March 8th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year sales of $31.11 million for the current fiscal year, with estimates ranging from $28.70 million to $33.00 million. For the next financial year, analysts anticipate that the company will post sales of $20.32 million, with estimates ranging from $12.00 million to $31.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Pieris Pharmaceuticals.

A number of analysts have recently issued reports on PIRS shares. BidaskClub raised Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 16th. HC Wainwright set a $5.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 7th. ValuEngine lowered Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 10th. Finally, Cowen reaffirmed a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Sunday, November 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Pieris Pharmaceuticals has an average rating of “Buy” and an average price target of $10.00.

Shares of NASDAQ PIRS opened at $3.03 on Tuesday. Pieris Pharmaceuticals has a 1 year low of $2.39 and a 1 year high of $9.75. The stock has a market cap of $153.79 million, a PE ratio of -7.58 and a beta of 1.87.

Several hedge funds and other institutional investors have recently made changes to their positions in PIRS. SG Americas Securities LLC purchased a new stake in shares of Pieris Pharmaceuticals during the fourth quarter worth about $36,000. Prudential Financial Inc. purchased a new stake in shares of Pieris Pharmaceuticals during the fourth quarter worth about $43,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Pieris Pharmaceuticals during the second quarter worth about $110,000. Rhumbline Advisers increased its position in shares of Pieris Pharmaceuticals by 51.5% during the fourth quarter. Rhumbline Advisers now owns 66,836 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 22,720 shares during the last quarter. Finally, California Public Employees Retirement System bought a new stake in Pieris Pharmaceuticals in the second quarter valued at about $179,000. 67.04% of the stock is currently owned by institutional investors and hedge funds.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Recommended Story: What is the yield curve?

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply